Chapter 5 Natural products: a continuing source of inspiration for the medicinal chemist

Advances in Phytomedicine

Volumn 1, Issue C, 2002, Pages 61-69

  Efange, S Mbua Ngale ^a  

^a NONE

Author keywords

drug development; medicinal chemistry; natural products; pharmacology

Indexed keywords

EID: 56449126272     PISSN: 1572557X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1572-557X(02)80014-9     Document Type: Chapter

References (38)

1. Robbers J.E., Speedie M.K., and Tyler V.E. Pharmacognosy and pharmacobiotechnology (1996), Williams & Wilkins, Philadelphia, PA
2. Farnsworth N.R., Akerele O., Bingel A.S., Soejarto D.D., and Guo Z. Medicinal plants in therapy. Bull. WHO 63 (1985) 965-981
3. Buss A.D., and Waigh R.D. Natural products as leads for new pharmaceuticals. In: Wolff M.E. (Ed). Burger's medicinal chemistry (1995), Wiley, New York 983-1033
4. Dybowski J., and Landrin E. Sur l'iboga, sur ses propriétés excitantes, sa composition et sur l'alcaloïde nouveau qui renferme. Compt Rend 133 (1901) 748-750
5. Haller A., and Heckel E. Sur l'iboga, principe actif d'une plante du genre Tabernanaemontana, originaire du Congo. Compt Rend 133 (1901) 850-853
6. Popik P., Layer R.T., and Skolnick P. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol Rev 47 (1995) 235-253
7. Rezvani A.H., Overstreet D.H., and Lee Y.-W. Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring rats. Pharmacol Biochem Behav 52 (1995) 615-620
8. Benwell M.E., Holtom P.E., Moran R.J., and Balfour D.J. Neurochemical and behavioral interactions between ibogaine and nicotine in the rat. Br J Pharmacol 117 (1996) 743-749
9. Maisonneuve I.M., Mann G.L., Deibel C.R., and Glick S.D. Ibogaine and the dopamine response to nicotine and the dopamine response to nicotine. Psychopharmacology 129 (1997) 249-256
10. US Patent No. 4,499,096. Lotsof H.S. Rapid method for interrupting the narcotic addiction syndrome (1985)
11. US Patent No. 4,587,243. Lotsof H.S. Rapid method for interrupting the cocaine and amphetamine abuse syndrome (1987)
12. Kaplan C.D., Ketzer E., De Jong J., and De Vries M. Reaching a stage of wellness: multistage explorations in social neuroscience. Soc Neurosci Bull 6 (1993) 6-7
13. Sisko B. Interrupting drug dependency with ibogaine: a summary of four case histories. Multidisc Assoc Psychedelic Stud 4 (1993) 15-24
14. Cannon J.G. Analog Design. In: Wolff M.E. (Ed). Burger's medicinal chemistry (1995), Wiley, New York 783-802
15. Hester J.B., Tang A.H., Keasling H.H., and Veldkamp W. Azepinoindoles. I. Hexahydroazepinol[4,5-b]indoles. J Med Chem 11 (1968) 101-106
16. Elliot A.J., Gold E.H., and Guzik H. Synthesis of some 5-phenylhexahydroazepino[4,5-b]indoles as potential neuroleptic agents. J Med Chem 23 (1980) 1268-1269
17. Efange S.M.N., Mash D.C., Khare A.B., and Ouyang Q. Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5,6-hexahydroazepino[4,5-b] benzothiophenes. J Med Chem 41 (1998) 4486-4491
18. Woolverton W.L., and Johnson K.M. Neurobiology of cocaine abuse. Trends Pharmacol Sci 13 (1992) 193-200
19. Nestler E.J. Cellular responses to chronic treatment with drugs of abuse. Crit Rev Neurobiol 7 (1993) 23-39
20. Mash D.C., Staley J.K., Baumann M.H., Rothman R.B., and Hearn W.L. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci 57 (1995) PL45-PL50
21. Staley J.K., Ouyang Q., Pablo J., Hearn W.L., Flynn D.D., Rothman R.B., Rice K.C., and Mash D.C. Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine. Psychopharmacology 127 (1996) 10-18
22. Glick S.D., Maisonneuve I.M., and Pearl S.M. Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine. Brain Res 749 (1997) 340-343
23. Codd E.E. High affinity ibogaine binding to a mu opioid agonist site. Life Sci 57 (1995) PL315-PL320
24. Pablo J.P., and Mash D.C. Noribogaine stimulates naloxone-sensitive [35S]GTPgS binding. NeuroReport 9 (1998) 109-114
25. Mash D.C., Staley J.K., Pablo J.P., Holohean A.M., Hackman J.C., and Davidoff R.A. Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neurosci Lett 192 (1995) 53-56
26. Popik P., Layer R.T., Fossom L.H., Benveniste M., Geter-Douglass B., Witkin J.M., and Skolnick P. NMDA antagonist properties of the putative anti-addictive drug, ibogaine. J Pharmacol Exptl Ther 275 (1995) 753-760
27. Sershen H., Hashim A., and Lajtha A. The effect of ibogaine on sigma- and NMDA-receptormediated release of [3H]dopamine. Brain Res Bull 40 (1996) 63-67
28. Chen K., Kokate T.G., Donevan S.D., Carroll F.I., and Rogawski M.A. Ibogaine blockade of the NMDA receptor: in vitro and in vivo studies. Neuropharmacology 35 (1996) 423-431
29. Layer R.T., Skolnick P., Bertha C.M., Bandarage U.K., Kuehne M.E., and Popik P. Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors. Eur J Pharmacol 309 (1996) 159-165
30. Bowen W.D., Vilner B.J., Williams W., Bertha C.M., Kuehne M.E., and Jacobson A.E. Ibogaine and its cogeners are sigma-2 receptors-selective ligands with moderate affinity. Eur J Pharmacol 279 (1995) R1-R3
31. Mach R.H., Smith C.R., and Childers S.R. Ibogaine possesses a selective affinity for _2 receptors. Life Sci 57 (1995) PL57-PL62
32. Schneider A.S., Nagel J.E., and Mah S.J. Ibogaine selectively inhibits nicotinic receptor-mediated catecholamine release. Eur J Pharmacol 317 (1996) R1-R2
33. Badio B., Padgett W.L., and Daly J.W. Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotonic receptors. Mol Pharmacol 51 (1997) 1-5
34. Hitzig P. Combined dopamine and serotonin agonists: a synergistic approach to alcoholism and other addictive behaviors. Med Med J 42 (1993) 153-156
35. Crooks P.A., and Szyndler R. Synthesis and analgestic properties of some conformationally restricted analogs of profadol. J Med Cem 23 (1980) 679-682
36. Crooks P.A., and Sommerville R. The synthesis and analgesic activities of some spiro[indan-1,3′-pyrrolidine] derivatives designed as rigid analogs of profadol. J Pharm Sci 71 (1982) 291-294
37. Bogeso K.P., Christensen A.V., Hyttel J., and Liljefors T. 3-Phenyl-1-indanamines. Potential antidepressant activity and potent inhibition of dopamine, norepinephrine, and serotonin uptake. J Med Chem 28 (1985) 1817-1828
38. US Patent No. 5,948,807. Efange S.M.N., and Mash D.C. Spiroindanamines and spiroindanamides (1999)